A.A. Ritchie

TL;DR: High activity coupled to non cross-resistance in cisplatin resistant models merit further development of this novel group of anticancer compounds.

TL;DR: It is highlighted that choice of age is inconsistent across the research community and often not based on the development or cellular ageing of the system being studied, which could potentially result in decreased scientific validity and increased experimental variability.

TL;DR: The results indicate that broad spectrum neuropeptide antagonists can inhibit the growth of SCLC in vivo and suggest that these antagonists could be useful in the treatment of S CLC.

TL;DR: The modulating effects of the orally active epidermal growth factor receptor-specific tyrosine kinase inhibitor ZD 1839 (‘Iressa’) on cell growth and signalling were evaluated in four ovarian cancer cell lines and lend further support to the view that targeting the epidersmal growthFactor receptor in ovarian cancer could have therapeutic benefit.

TL;DR: Antisense oligodeoxynucleotides (ODNs) reduced c-Raf protein levels and inhibited cell proliferation in vitro and in vivo and use of antisense ODNs targeted to c- Raf could provide a strategy for the treatment of this disease.